Advertisement
Belzutifan superior to everolimus in phase 3 clinical trial
Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial
Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia
San Antonio Breast Cancer Symposium presentations underscore safety of assisted reproductive technology and pregnancy in women during and after breast cancer treatment
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study offers a foundation for additional research to examine radiation and immune response
Researchers compared tacrolimus/methotrexate to tacrolimus and reduced-dose methotrexate/mycophenolate
Cleveland Clinic radiation oncologists aim to bring the noninvasive approach back to the U.S., where use has declined
Targeting DNMT1 shows promise in chemotherapy- and immunotherapy-resistant SCLC
Immunological pressure driving genetic mutations
New review published in Cancers suggests a synergistic benefit
Advertisement
Advertisement